H Lundbeck has announced results from an open-label phase 1b trial evaluating Lu AF28996, a novel, investigational, oral prodrug of D1-like/D2-like dopamine receptor agonist, in people with advanced Parkinson’s disease experiencing motor symptoms sub-optimally controlled despite optimised non-invasive antiparkinsonian medication.
The results are being presented at the International Congress of Parkinson’s Disease and Movement Disorders (MDS) 2026 in Seoul, South Korea.
Parkinson’s disease is characterised by the progressive degeneration of dopamine-producing neurons in the brain.
While levodopa remains the cornerstone of symptomatic treatment, many people experience difficult-to-manage motor complications as the disease progresses.
These include fluctuations between periods of good symptom control (ON-time) and periods when symptoms return or worsen (OFF-time), and treatment-related dyskinesia (involuntary movements) despite optimised treatment.
For people with advanced Parkinson’s disease, many treatment options involve invasive procedures or continuous drug delivery, requiring patients to meet specific eligibility criteria.
There remains a need for effective, well-tolerated and non-invasive treatment approaches that can provide more consistent motor control.
